MHRA on COX-2s
This article was originally published in The Tan Sheet
Executive Summary
"Evidence suggests that selective COX-2 inhibitors, as a class, may cause an increased risk of thrombotic events compared with placebo and some NSAIDs, and the risk may increase with dose and duration of exposure," Gordon Duff, chairman, UK Committee on Safety of Medicines, states in a Feb. 17 letter to physicians. The notice provides an update on COX-2 safety "following a European-wide review" of cardiovascular data. "The lowest effective dose of COX-2 inhibitor should be used for the shortest necessary period," the letter says...